For years, developing selective FGFE2/3 inhibitors has been hindered by the extreme structural similarity among FGFR family members, leading to toxicities and resistance with current therapies.

Chaopeng Shen and Yalan Song, two researchers in the Penn State College of Civil and Environmental Engineering, developed an ...